{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T06:05:26Z","timestamp":1760853926931},"reference-count":42,"publisher":"Impact Journals, LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,1,3]]},"DOI":"10.18632\/oncotarget.13557","type":"journal-article","created":{"date-parts":[[2016,11,24]],"date-time":"2016-11-24T19:27:35Z","timestamp":1480015655000},"page":"742-756","source":"Crossref","is-referenced-by-count":23,"title":["Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signaling in chronic lymphocytic leukemia cells"],"prefix":"10.18632","volume":"8","author":[{"given":"Noelia","family":"Purroy","sequence":"first","affiliation":[{"name":"Laboratory of Experimental Hematology, Department of Hematology, Vall d'Hebron University Hospital, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00falia","family":"Carabia","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Hematology, Department of Hematology, Vall d'Hebron University Hospital, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pau","family":"Abrisqueta","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Hematology, Department of Hematology, Vall d'Hebron University Hospital, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leire","family":"Egia","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Hematology, Department of Hematology, Vall d'Hebron University Hospital, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meritxell","family":"Aguil\u00f3","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Hematology, Department of Hematology, Vall d'Hebron University Hospital, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilia","family":"Carpio","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Hematology, Department of Hematology, Vall d'Hebron University Hospital, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carles","family":"Palacio","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Hematology, Department of Hematology, Vall d'Hebron University Hospital, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Crespo","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Hematology, Department of Hematology, Vall d'Hebron University Hospital, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesc","family":"Bosch","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Hematology, Department of Hematology, Vall d'Hebron University Hospital, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2016,11,24]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1056\/NEJMra041720","article-title":"Chronic lymphocytic leukemia","volume":"352","author":"Ferrarini","year":"2005","journal-title":"N Engl J Med"},{"key":"2","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1182\/blood.V96.8.2655","article-title":"Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1","volume":"96","author":"Kipps","year":"2000","journal-title":"Blood"},{"key":"3","doi-asserted-by":"publisher","first-page":"4313","DOI":"10.1182\/blood-2011-06-338855","article-title":"B-cell receptor signaling in chronic lymphocytic leukemia","volume":"118","author":"Packham","year":"2011","journal-title":"Blood"},{"key":"4","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1182\/blood-2010-05-284984","article-title":"The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia","volume":"117","author":"McCoy","year":"2011","journal-title":"Blood"},{"key":"5","doi-asserted-by":"publisher","first-page":"4609","DOI":"10.1182\/blood-2002-06-1683","article-title":"Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia","volume":"100","author":"Kipps","year":"2002","journal-title":"Blood"},{"key":"6","doi-asserted-by":"publisher","first-page":"3584","DOI":"10.1182\/blood-2005-04-1718","article-title":"ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL)","volume":"107","author":"Prentice","year":"2006","journal-title":"Blood"},{"key":"7","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Heerema","year":"2013","journal-title":"N Engl J Med"},{"key":"8","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/S1470-2045(13)70513-8","article-title":"Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b\/2 trial","volume":"15","author":"Heerema","year":"2014","journal-title":"Lancet Oncol"},{"key":"9","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/oxfordjournals.jbchem.a002970","article-title":"Structure and function of Syk protein-tyrosine kinase","volume":"130","author":"Yamamura","year":"2001","journal-title":"J Biochem (Tokyo)"},{"key":"10","doi-asserted-by":"publisher","first-page":"5424","DOI":"10.1158\/0008-5472.CAN-08-4252","article-title":"Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia","volume":"69","author":"Dierks","year":"2009","journal-title":"Cancer Res"},{"key":"11","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1038\/leu.2008.346","article-title":"Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells","volume":"23","author":"Efremov","year":"2009","journal-title":"Leukemia"},{"key":"12","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1182\/blood-2009-03-212837","article-title":"B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406","volume":"114","author":"Burger","year":"2009","journal-title":"Blood"},{"key":"13","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1182\/blood-2009-08-236471","article-title":"Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia","volume":"115","author":"Sterba","year":"2010","journal-title":"Blood"},{"key":"14","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1038\/leu.2013.37","article-title":"Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia","volume":"27","author":"Friedberg","year":"2013","journal-title":"Leukemia"},{"key":"15","doi-asserted-by":"publisher","first-page":"7632","DOI":"10.18632\/oncotarget.2939","article-title":"Co-culture of primary CLL cells with bone marrow mesenchymal cells, CD40 ligand and CpG ODN promotes proliferation of chemoresistant CLL cells phenotypically comparable to those proliferating","volume":"6","author":"Crespo","year":"2014","journal-title":"Oncotarget"},{"key":"16","doi-asserted-by":"publisher","first-page":"4820","DOI":"10.1182\/blood-2004-07-2669","article-title":"Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells","volume":"105","author":"Efremov","year":"2005","journal-title":"Blood"},{"key":"17","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1182\/blood-2011-07-370403","article-title":"Surface IgM stimulation induces MEK1\/2-dependent MYC expression in chronic lymphocytic leukemia cells","volume":"119","author":"Packham","year":"2012","journal-title":"Blood"},{"key":"18","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/sj.leu.2404417","article-title":"The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease","volume":"21","author":"Efremov","year":"2007","journal-title":"Leukemia"},{"key":"19","doi-asserted-by":"publisher","first-page":"e79987","DOI":"10.1371\/journal.pone.0079987","article-title":"Multidimensional single-cell analysis of BCR signaling reveals proximal activation defect as a hallmark of chronic lymphocytic leukemia B cells","volume":"9","author":"Seymour","year":"2014","journal-title":"PloS One"},{"key":"20","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1182\/blood-2007-04-083832","article-title":"CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells","volume":"110","author":"Chiorazzi","year":"2007","journal-title":"Blood"},{"key":"21","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1182\/blood-2007-05-092882","article-title":"Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia","volume":"112","author":"Rai","year":"2008","journal-title":"Blood"},{"key":"22","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1084\/jem.184.3.1101","article-title":"A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1)","volume":"184","author":"Springer","year":"1996","journal-title":"J Exp Med"},{"key":"23","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1182\/blood.V94.11.3658","article-title":"Chronic Lymphocytic Leukemia B Cells Express Functional CXCR4 Chemokine Receptors That Mediate Spontaneous Migration Beneath Bone Marrow Stromal Cells","volume":"94","author":"Kipps","year":"1999","journal-title":"Blood"},{"key":"24","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1084\/jem.20030169","article-title":"Cooperating mechanisms of CXCR5 and CCR7 in development and organization of secondary lymphoid organs","volume":"197","author":"F\u00f6rster","year":"2003","journal-title":"J Exp Med"},{"key":"25","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1038\/leu.2014.96","article-title":"Targeting the proliferative and chemoresistant compartment in chronic lymphocytic leukemia by inhibiting survivin protein","volume":"28","author":"Bosch","year":"2014","journal-title":"Leukemia"},{"key":"26","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/leu.2014.263","article-title":"Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors","volume":"29","author":"Wang","year":"2015","journal-title":"Leukemia"},{"key":"27","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/0092-8674(92)90598-7","article-title":"ZAP-70: a 70 kd protein-tyrosine kinase that associates with the TCR zeta chain","volume":"71","author":"Weiss","year":"1992","journal-title":"Cell"},{"key":"28","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","article-title":"Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes","volume":"122","author":"Frissora","year":"2013","journal-title":"Blood"},{"key":"29","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3324\/haematol.2014.107011","article-title":"Ibrutinib interferes with the cell-mediated anti-tumour activities of therapeutic CD20 antibodies: implications for combination therapy","volume":"100","author":"Golay","year":"2014","journal-title":"Haematologica"},{"key":"30","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1124\/jpet.106.109058","article-title":"R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation","volume":"319","author":"Sun","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"31","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1182\/blood-2014-08-595934","article-title":"An open-label phase 2 trial of entospletinib (GS-9973), a selective Syk inhibitor, in chronic lymphocytic leukemia","volume":"125","author":"Yasenchak","year":"2015","journal-title":"Blood"},{"key":"32","first-page":"5s","article-title":"Antitumor activity of inhibiting SYK kinase with TAK-659, an investigational agent, in DLBCL models","volume":"32","author":"Kannan","year":"2014","journal-title":"J Clin Oncol"},{"key":"33","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1002\/hon.2227","article-title":"Ongoing, first-in-human, phase 1 dose-escalation study of investigational Syk inhibitor TAK-659 in patients with advanced solid tumours or lymphoma","author":"Shih","year":"2015","journal-title":"Hematological Oncology"},{"key":"34","doi-asserted-by":"publisher","first-page":"3797","DOI":"10.1182\/blood-2013-10-534073","article-title":"Stimulation of the B-cell receptor activates the JAK2\/STAT3 signaling pathway in chronic lymphocytic leukemia cells","volume":"123","author":"Keating","year":"2014","journal-title":"Blood"},{"key":"35","doi-asserted-by":"publisher","first-page":"4894","DOI":"10.1182\/blood-2010-03-275180","article-title":"The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the E\u03bc- TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling","volume":"116","author":"Efremov","year":"2010","journal-title":"Blood"},{"key":"36","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.1182\/blood-2013-11-535047","article-title":"Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110\u03b4, for relapsed\/refractory chronic lymphocytic leukemia","volume":"123","author":"Li","year":"2014","journal-title":"Blood"},{"key":"37","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1182\/blood-2011-10-386417","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homingand","volume":"119","author":"Burger","year":"2012","journal-title":"Blood"},{"key":"38","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1182\/blood-2010-02-271171","article-title":"Phosphatidylinositol 3-kinase-\u03b4 inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals","volume":"116","author":"Wei","year":"2010","journal-title":"Blood"},{"key":"39","doi-asserted-by":"publisher","first-page":"6287","DOI":"10.1182\/blood-2011-01-328484","article-title":"Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765","volume":"117","author":"Byrd","year":"2011","journal-title":"Blood"},{"key":"40","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.1182\/blood-2011-05-352492","article-title":"The phosphoinositide 3\u2032-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia","volume":"118","author":"Burger","year":"2011","journal-title":"Blood"},{"key":"41","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1182\/blood-2014-01-547869","article-title":"Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity","volume":"123","author":"Byrd","year":"2014","journal-title":"Blood"},{"key":"42","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.13557","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,10]],"date-time":"2020-05-10T13:28:07Z","timestamp":1589117287000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.13557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,24]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1,3]]}},"alternative-id":["13557","27888629"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.13557","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,24]]}}}